| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Alpine Immune Sciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$64.97 |
| 52 Week High | US$65.00 |
| 52 Week Low | US$8.33 |
| Beta | 0.97 |
| 11 Month Change | 0.65% |
| 3 Month Change | 113.79% |
| 1 Year Change | 518.17% |
| 33 Year Change | 520.53% |
| 5 Year Change | 1,270.68% |
| Change since IPO | 580.31% |
Recent News & Updates
Recent updates
Alpine: Vertex Acquisition Brings About More Than IgA Nephropathy Advancement
Apr 11Earnings Update: Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Just Reported And Analysts Are Trimming Their Forecasts
Mar 21
Here's Why We're Not Too Worried About Alpine Immune Sciences' (NASDAQ:ALPN) Cash Burn Situation
Mar 20Alpine Immune Sciences: Track Record Undermines Case For Latest Lead Drug
Mar 07Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) Shares Climb 41% But Its Business Is Yet to Catch Up
Feb 07Alpine Immune Sciences, Inc.'s (NASDAQ:ALPN) 41% Share Price Surge Not Quite Adding Up
Dec 19We Think Alpine Immune Sciences (NASDAQ:ALPN) Can Afford To Drive Business Growth
Sep 23Revenues Not Telling The Story For Alpine Immune Sciences, Inc. (NASDAQ:ALPN)
May 11Is Alpine Immune Sciences (NASDAQ:ALPN) Weighed On By Its Debt Load?
Dec 12Alpine Immune Sciences drops 13% after hours on $100M stock offering
Sep 20Despite Lacking Profits Alpine Immune Sciences (NASDAQ:ALPN) Seems To Be On Top Of Its Debt
Aug 09Alpine: Rest Before Rallying Again
Apr 25Is Alpine Immune Sciences (NASDAQ:ALPN) A Risky Investment?
Apr 12Rock star Growth Puts Alpine Immune Sciences (NASDAQ:ALPN) In A Position To Use Debt
Sep 18Industry Analysts Just Upgraded Their Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Revenue Forecasts By 42%
Aug 18Shareholder Returns
| ALPN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.03% | -0.7% | -1.6% |
| 1Y | 518.2% | 19.8% | 30.8% |
Return vs Industry: ALPN exceeded the US Biotechs industry which returned 5.8% over the past year.
Return vs Market: ALPN exceeded the US Market which returned 26% over the past year.
Price Volatility
| ALPN volatility | |
|---|---|
| ALPN Average Weekly Movement | 13.8% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: ALPN's share price has been volatile over the past 3 months.
Volatility Over Time: ALPN's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 142 | Mitch Gold | www.alpineimmunesciences.com |
Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company’s product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus.
Alpine Immune Sciences, Inc. Fundamentals Summary
| ALPN fundamental statistics | |
|---|---|
| Market cap | US$4.46b |
| Earnings (TTM) | -US$36.84m |
| Revenue (TTM) | US$56.52m |
78.9x
P/S Ratio-121.0x
P/E RatioIs ALPN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALPN income statement (TTM) | |
|---|---|
| Revenue | US$56.52m |
| Cost of Revenue | US$83.78m |
| Gross Profit | -US$27.26m |
| Other Expenses | US$9.58m |
| Earnings | -US$36.84m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.54 |
| Gross Margin | -48.23% |
| Net Profit Margin | -65.17% |
| Debt/Equity Ratio | 0% |
How did ALPN perform over the long term?
See historical performance and comparison